S. de Miranda

发表

First Wave of COVID-19 in French Patients with Cystic Fibrosis

P. Boelle, P. Burgel, L. Guillot, 2020, Journal of clinical medicine.

High Emergency Lung Transplantation: dramatic decrease of waiting list death rate without relevant higher post‐transplant mortality

M. Stern, D. Grenet, E. Cuquemelle, 2015, Transplant international : official journal of the European Society for Organ Transplantation.

Clinical picture of Pneumocystis jiroveci pneumonia in cancer patients.

É. Azoulay, B. Schlemmer, C. Sarfati, 2007, Chest.

Cumulative Incidence and Risk Factors for Severe COVID-19 in French People with Cystic Fibrosis

P. Reix, P. Burgel, C. Marguet, 2022, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Intensive care in patients with newly diagnosed malignancies and a need for cancer chemotherapy*

J. le Gall, É. Azoulay, M. Darmon, 2005, Critical care medicine.

Minimally Invasive Diagnostic Strategy in Immunocompromised Patients with Pulmonary Infiltrates

É. Azoulay, A. Kouatchet, D. Schnell, 2010, Pulmonary Involvement in Patients with Hematological Malignancies.

[Diagnostic strategy for acute respiratory failure in patients with haematological malignancy].

É. Azoulay, B. Schlemmer, S. De miranda, 2008, Revue des maladies respiratoires.

Antibody‐Mediated Rejection in Lung Transplantation: Clinical Outcomes and Donor‐Specific Antibody Characteristics

Kimberly A. Thomas, R. Spreafico, A. Roux, 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

Outcome of cancer patients considered for intensive care unit admission: a hospital-wide prospective study.

J. le Gall, É. Azoulay, M. Darmon, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Continuous infusion of ceftolozane/tazobactam is associated with a higher probability of target attainment in patients infected with Pseudomonas aeruginosa

M. Legrand, B. Pilmis, A. Le Monnier, 2019, European Journal of Clinical Microbiology & Infectious Diseases.

Airway microbiota signals anabolic and catabolic remodeling in the transplanted lung

C. Auffray, R. Slama, J. Vincent, 2017, The Journal of allergy and clinical immunology.

Respiratory status deterioration during G-CSF-induced neutropenia recovery

É. Azoulay, M. Darmon, B. Schlemmer, 2005, Bone Marrow Transplantation.

Intensive care unit admission in chronic obstructive pulmonary disease: patient information and the physician’s decision-making process

T. Similowski, N. Roche, É. Azoulay, 2014, Critical Care.

Real-Life Safety and Effectiveness of Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis.

D. Caimmi, A. Didier, S. Leroy, 2020, American journal of respiratory and critical care medicine.

Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy

V. Paradis, V. Vilgrain, F. Mellot, 2017, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Postintensive care unit psychological burden in patients with chronic obstructive pulmonary disease and informal caregivers: A multicenter study

A. Cuvelier, T. Similowski, N. Roche, 2011, Critical care medicine.

2022 Update of indications and contraindications for lung transplantation in France.

M. Humbert, E. Fadel, P. Mordant, 2022, Respiratory medicine and research.

Characteristics of Donor-Specific Antibodies Associated With Antibody-Mediated Rejection in Lung Transplantation

Kimberly A. Thomas, M. Rossetti, M. Stern, 2017, Front. Med..

Blood CD9+ B cell, a biomarker of bronchiolitis obliterans syndrome after lung transplantation

R. Slama, Y. Castier, J. Pellet, 2019, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

A virtual crossmatch-based strategy for perioperative desensitisation in lung transplant recipients with pre-formed donor-specific antibodies: 3-year outcome

M. Neuville, A. Vallée, D. Grenet, 2021, European Respiratory Journal.

AGER -429T/C Is Associated with an Increased Lung Disease Severity in Cystic Fibrosis

P. Böelle, P. Reix, J. Dalphin, 2012, PloS one.

[Updated indications and contraindications in 2022 for lung transplantation in France].

P. Mordant, P. Burgel, V. Cottin, 2022, Revue des maladies respiratoires.

Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

C. Goss, H. Rodgers, P. Burgel, 2022, Journal of Cystic Fibrosis.

Results of Lung Transplantation for Cystic Fibrosis With Selected Donors Over 65 Years Old

M. Stern, D. Grenet, C. Cerf, 2023, Transplant International.

Blood MMP-9 measured at 2 years after lung transplantation as a prognostic biomarker of chronic lung allograft dysfunction

S. Delliaux, O. Collange, F. Daviet, 2024, Respiratory research.